


Share Our Vision

We strive to transform vision by pioneering unique, dropless platforms that can meaningfully advance the standard of care and improve outcomes for all patients living with glaucoma, the second leading cause of blindness in the US and around the globe.¹

How the iDose Your Dose Initiative Works

For every iDose® TR sold, Glaukos pledges to provide an equal number of iDose TR units for qualifying charitable donation requests around the globe.*

*Recipients of Glaukos product donations must satisfy independent eligibility requirements.



iDose TR for Glaucoma

iDose TR is a long duration intracameral procedural pharmaceutical that delivers prostaglandin analog therapy for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.²

iDose TR continuously delivers therapeutic levels of travoprost, so patients receive the medication they need to help with long-term IOP control.²

Our Commitment

Glaukos is dedicated to addressing the greatest unmet needs in ophthalmology around the globe for patients and their physicians. We believe that ALL patients worldwide should have access to innovative glaucoma treatments, regardless of their circumstances. We believe in the principles of health equity and partner with people and organizations who share our values. In our efforts to help those in need receive the highest level of treatment, we work with foundations around the world to provide access to meaningful, safe, and long-term treatments for all people living with glaucoma.



- Kingman S. Glaucoma is second leading cause of blindness globally.
 Bull World Health Organ. 2004 Nov;82(11):887-8. 2004 Dec 14. PMID: 15640929; PMCID: PMC2623060.
 iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.

INDICATIONS AND USAGE

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

IMPORTANT SAFETY INFORMATION

DOSAGE AND ADMINISTRATION

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

CONTRAINDICATIONS

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

WARNINGS AND PRECAUTIONS

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

ADVERSE REACTIONS

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.



View full

prescribing information at

iDoseTRhcp.com